# MSCA op ECTRIMS 2023
## Presentations: 14, Posters: 28 (6 ePosters), Chair 5


## Wednesday, 11 October 2023

### Educational Session 4: Caring for older patients with MS
**Eva Strijbis** (CHAIR)
08:45 - 09:45 ROOM: Brown 3

**Recommendations on DMTs in aging patients**
**Eva Strijbis**
09:20 - 09:35


### Educational Session 2 (MAGNIMS): Imaging features of MOGAD and differential diagnosis with MS
08:45 - 09:45 ROOM: Auditorium

**Differentiating the appearances of MOGAD from MS AND AQP4 NMOSD**
**Frederik Barkhof**
09:05 - 09:20


### Free Communications 1: Imaging biomarkers
10:00 - 11:00 ROOM: Brown 1

**Brain atrophy is age-related in relapsing-remitting multiple sclerosis (**ID O022**)**
**Sezgi Kacar**
10:45 - 10:55


### Scientific Session 4: Effects of MS on cognition and beyond
14:30 - 16:00 ROOM: Red

**Identifying cognitive phenotypes in multiple sclerosis using machine learning models: a multicentre study** (ID 0038)
**Elisa Colato**
15.06 – 15.12

**Identifying cognitive profiles in MS: the role of memory functioning (**ID O040)
**Maureen van Dam**
15:19 - 15:26

**Cognitive progression independent of relapse in multiple sclerosis (**ID O041)
**Tom Fuchs**
15:26 - 15:33

**POSTERS  16:30 - 18:30 CEST**

**Symptom networks in people with MS: understanding the multidimensionality of psychological factors and cognitive functioning** P030
*Maureen van Dam*

**Risk of conversion to progressive multiple sclerosis in relapsing-remitting patients: development and validation of the DAAE risk score** P036
*Tom Fuchs*

**Investigating cognitive and physical functioning of people with MS in day-to-day life: extensive validation of the MS-IADL-Q** P079
*Maureen van Dam*

**Cortical atrophy explains the relation between cortical lesions and cognitive decline in people with multiple sclerosis** P164
*Eva Krijnen*

**Cortical atrophy in cognitive networks is worst in non-lesional cortex in people with multiple sclerosis** P165
*Eva Krijnen*

**Thalamic nuclei-specific microstructural alterations based on cell body and neurite density imaging in people with multiple sclerosis** P166
*Eva Krijnen*

**Enlarged choroid plexus volume in multiple sclerosis is related with disability, cognition and brain atrophy** P178
*Samantha Noteboom*

**Treatment with cladribine tablets is associated with slower regional atrophy: a retrospective study on atrophy patterns in multiple sclerosis** P187
*Mar Barrantes Cepas*

**Highly Sensitive Proteomic Immunoassays to Identify Novel Serum Biomarkers for Multiple Sclerosis Disease Progression in Natulizumab Treated Patients** P221
*Sjors in 't Veld*

**Advancing the understanding of cognitive impairment in MS through network measures and machine learning classification** P274
*Julia Jelgerhuis*

**Phase I trial of faecal microbiota transplantation in MS** P282
*Bob van Oosten*

**Age is associated with inflammatory disease acitivity in a relapsing-remitting multiple sclerosis clinical trial population** P313
*Sezgi Kacar*

**Influence of personalized extended interval dosing on the natalizumab wearing-off effect** P351
*Alyssa Toorop*

## Thursday, 12 October 2023

**Scientific Session 6: Imaging MS progression**
11:30 - 13:00 ROOM: Silver
**Frederik Barkhof (CHAIR)**

**Higher-order connectivity and cognitive impairment in MS (**ID O073)
**Tommy Broeders**
12:12 - 12:19

**Scientific Session 7: Body fluid biomarkers as surrogate of disease activity, progression and treatment response**
11:30 - 13:00 ROOM: Auditorium
**Joep Killestein** (CHAIR)

**Neurofilament light chain (**ID O076)
**Charlotte Teunissen**
11:35 - 11:50

**Scientific Session 10: Safety of different treatment algorithms for MS**
15:00 - 16:30 ROOM: Gold

**Prospective trial of natalizumab personalized extended interval dosing by therapeutic drug monitoring in relapsing remitting multiple sclerosis (NEXT-MS) (**ID O097)
**Alyssa Toorop**
15:35 - 15:35

**Discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS): an early-terminated multicenter randomized controlled trial** (ID O099)
**Eline Coerver**
15:35 - 15:35

**Young Scientific Investigators' Session 3: Imaging and non-imaging biomarkers**
15:00 - 16:00 ROOM: Blue

**Functional brain state dynamics in cognitively declining MS** (ID O128)
**Marloes Bet**
15:35 - 15:45

**POSTERS  17:00 - 19:00**

**The Impact of Information Processing Speed Deficits on Visuospatial Memory in Multiple Sclerosis: Preliminary Results** P430
*Pauline Waskowiak*

**Measuring spontaneous remyelination in a longitudinal multiple sclerosis cohort** P492
*Sam Hof*

**Identifying novel serum biomarkers for disease progression in ocrelizumab-treated multiple sclerosis using a proteomic immunoassay** P648
*Mark Wessels*

**Dynamic Imaging of Myelin Pathology with Third Harmonic Generation Imaging** P668
*Niels Meijns*

**Digital biomarkers are associated with brain atrophy and lesion volume in patients with multiple sclerosis** P671
*Pam Molenaar*

**Extended interval dosing of ocrelizumab modifies the repopulation of B-cell subsets without altering clinical efficacy in multiple sclerosis patients** P681
*Carla Rodriguez-Mogeda*

**No difference in radiological and clinical disease activity one year after initiation of natalizumab compared to ocrelizumab in patients with highly active multiple sclerosis: a retrospective cohort study** P689
*Laura Hogenboom*

**A randomised controlled trial for measuring and predicting the effect of remyelinating therapy in multiple sclerosis (RESTORE): Recruitment status** P705
*Sam Hof*

**Patient-reported outcome measures in discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS): results of a multicenter randomized controlled trial** P791
*Wing Hee Fung*

**Friday, 13 October 2023**

**Educational Session 15: Optimising monoclonal antibody treatment in MS**
08:45 - 09:45 ROOM: Red
**Joep Killestein** (CHAIR)
**Zoé van Kempen** (CHAIR)

**Finding the right dose/interval for monoclonal antibodies in MS** (ID O133)
**Zoé van Kempen**
08:50 - 09:05

**The differences and similarities of the various anti-CD20 therapies, is one superior to the others?**
(ID O135)
**Joep Killestein**
09:20 - 09:35

**Hot Topic 10: CNS damage, recovery and neuroplasticity**
12:00 - 13:00 ROOM: Brown 1

**Structural and functional MRI (**ID O178**)**
**Menno Schoonheim**
12:15 - 12:25

**ePosters**

**Variability of brain-age estimates in multiple sclerosis within and between three different MR scanners** P1321
*Lonneke Bos*

**Improving the clinical applicability of brain volume measurements; reliability of 3D-FLAIR is similar to 3D-T1 in MS** P1351
*David van Nederpelt*

**Highly Sensitive Proteomic Immunoassays to Identify Novel Biomarkers for Multiple Sclerosis Disease Progression in Ibudilast Treated Patients** P1386
*Sjors in 't Veld*

**Association of bioactive lipid mediators with white matter integrity changes in patients with relapsing remitting multiple sclerosis** P1399
*Wing Hee Fung*

**Serum neurofilament light in the clinic: comparing stabilization under natalizumab with ocrelizumab** P1401
*Mark Wessels*

**Predicting the risk of infusion-related reactions in ocrelizumab treatment** P1571
*Lisa Schoof*